---
format:
  revealjs:
    spotlight: true
    touch: true
    controls: true
    pointer: true
    center-title-slide: false
    transition: fade
    transition-speed: fast
    scrollable: true
    slide-number: true
    incremental: false
    multiplex: false
    chalkboard: true
    theme: [default, custom.scss]
    filters:
     - highlight-text
bibliography: references.bib
lightbox: true
csl: diagnostic-microbiology-and-infectious-disease.csl
---

## Lecture 5: β-lactams, Part 2: <br> Cephalosporins and carbapenems {background-image="images/Bronzu.png" background-opacity="0.1"}

<br> <br> <br> <br>

**Russell E. Lewis** <br> Associate Professor of Infectious Diseases <br> Department of Molecular Medicine <br> University of Padua

<br> {{< fa solid envelope size=1x >}} russelledward.lewis\@unipd.it <br> {{< fa brands github size=1x >}} [https://github.com/Russlewisbo](https://github.com/Russlewisbo/ESCMID_2022_talk)

![](images/University_of_Padua_seal.svg){width="100"}

## Agenda

## Discovery of cephalosporins {.smaller}

<br>

::::: columns
::: {.column width="40%"}
![](images/Bronzu.png){width="800"}
:::

::: {.column width="60%"}
<br>

-   Bronzu performed epidemiological studies of typhoid infection in Cagliari, noted *Salmonella typhi* was not cultured once sewer water was discharged into the sea
-   Isolated the mold *Cephalosporium* (now known as *Acremonium*) in 1948 from seawater
-   Noticed that these cultures produced substances (he named mycetin) that were effective against *Salmonella typhi*, the cause of typhoid fever, which had beta-lactamase.
-   After he failed to find support from Italian government, he sent the fungus to Howard Florey at Oxford
-   1962: Isolation of cephalosporin C
:::
:::::

## Mechanism of action of cephalosporins: <br> Same as β-lactams

<br>

::::: columns
::: {.column width="50%"}
![Inhibition of transpeptidase (PBP)](https://i.makeagif.com/media/4-07-2017/l7_PRO.gif)
:::

::: {.column width="50%"}
![Lysis of growing bacterial cells](https://i.makeagif.com/media/10-05-2017/e3c7kf.gif)
:::
:::::

<br>

## First generation cephalosporins; <br> derivatives of 7-ACA {.smaller}

![](images/1gen.png){fig-align="center" width="400"}

::: aside
-   Gram positive activity: Cover Methicillin-sensitive *S. aureus* (MSSA) and streptococci:
-   Used for uncomplicated skin and soft-tissue infections (SSI)
-   Surgical prophylaxis: cefazolin
-   Some Gram negative coverage in urine: *P. mirabilis, E. coli, and K. pneumoniae*
:::

## Pharmacokinetics: 1st generation cephalosporins {.smaller}

<br> <br>

+-------------------+-------------------------------------------------------------------+
| **Absorption**    | Cefadroxil (90%); cephalexin (90%); cefazolin (IV only)           |
+-------------------+-------------------------------------------------------------------+
| **Distribution**  | -   0.19-0.35 L/kg                                                |
|                   |                                                                   |
|                   | -   Protein binding: 20% cefadroxil, cephalexin; 73-87% cefazolin |
|                   |                                                                   |
|                   | -   25% bile:serum; cefazolin:29-300%                             |
|                   |                                                                   |
|                   | -   5-10% CSF:blood (possibly for cefazolin with higher doses)    |
+-------------------+-------------------------------------------------------------------+
| **Metabolism**    | -   No metabolism                                                 |
|                   |                                                                   |
|                   | -   t½: Cefazolin (2 hrs); cefadroxil (1.5 hrs); cephalexin (1hr) |
+-------------------+-------------------------------------------------------------------+
| **Elimination**   | Renal 100%, impaired by probenicid                                |
+-------------------+-------------------------------------------------------------------+
| **PK:PD target**  | ≥ 40-50% *f*Time~\>MIC~                                           |
+-------------------+-------------------------------------------------------------------+
| **Typical doses** | Cefazolin: 1-2 gram IV every 8 hours                              |
|                   |                                                                   |
|                   | Cefadroxil: 500-1000 mg BID                                       |
|                   |                                                                   |
|                   | Cephalexin 250-1000 mg QID                                        |
+-------------------+-------------------------------------------------------------------+

::: aside
Source: Sanford Guide
:::

## Avoid cefazolin for CNS infections?

<br>

::::: columns
::: {.column width="50%"}
![](images/myth1.png)
:::

::: {.column width="50%"}
![](images/myth2.png)
:::
:::::

::: aside
[@mccreary.etal_2023b]
:::

## Why this myth has been busted?

<br>

-   **Earlier recommendations based on breakthrough reports with cephalothin and single point samples suggesting low CSF concentrations**
-   **More recent data have documented attainment of therapeutic exposures with higher dose regimens:**
    -   A recent narrative review on the treatment of cefazolin for CNS infections (including 11 reports describing cefazolin treatment of spinal epidural abscesses in a total of 104 patients) recommends [2 g IV every 6 hours or a continuous infusion of 8–10 g daily]{bg-color="#ffe536"} instead of the traditional 1–2 g IV every 8 hours dosing scheme to optimize pharmacokinetic/pharmacodynamic properties

::: aside
[@antosz.etal_2023a]
:::

## Another cefazolin myth busted? <br> penicillin cross-allergy {.smaller}

<br>

::::: columns
::: {.column width="50%"}
![](images/myth3.png){width="500"}
:::

::: {.column width="50%"}
![](images/myth4.png){width="600"}
:::
:::::

::: aside
[@mccreary.etal_2023b]
:::

## Second generation cephalosporins {.smaller}

![](images/2ndgen.png){fig-align="center" width="800"}

## Spectrum of activity {.smaller}

<br>

![](images/spectrum.png){fig-align="center"}

::: aside
Source. Sanford's Guide
:::

## Pharmacokinetics of representative 2nd generation cephalosporins {.smaller}

<br> <br>

+-------------------+--------------------------------------------------------------------------+
| **Absorption**    | Cefuroxime (52%), cefprozil (95%), cefaclor (93%)                        |
+-------------------+--------------------------------------------------------------------------+
| **Distribution**  | -   0.15-0.35 L/kg                                                       |
|                   |                                                                          |
|                   | -   Protein binding: 36-50%                                              |
|                   |                                                                          |
|                   | -   25% bile:serum; cefazolin:29-300%                                    |
|                   |                                                                          |
|                   | -   5-10% CSF:blood (possibly for cefazolin with higher doses)           |
+-------------------+--------------------------------------------------------------------------+
| **Metabolism**    | -   No metabolism                                                        |
|                   |                                                                          |
|                   | -   t½:cCefuroxime (1.5hrs); cefadroxil (1.5 hrs); cefotetan( 3-4 hr) \| |
+-------------------+--------------------------------------------------------------------------+
| **Elimination**   | Renal 100%                                                               |
+-------------------+--------------------------------------------------------------------------+
| **PK:PD target**  | ≥ 40-50% *f*Time~\>MIC~                                                  |
+-------------------+--------------------------------------------------------------------------+
| **Typical doses** | cefaclor: 250-500 mg TID                                                 |
|                   |                                                                          |
|                   | cefuroxime: 250-500 BID                                                  |
|                   |                                                                          |
|                   | cefotetan: 1-2 gram IV q12h                                              |
+-------------------+--------------------------------------------------------------------------+

::: aside
Source: Sanford Guide
:::

## 2nd generation cephalosporins: <br> What is their role?

<br>

-   Cefotetan- GI surgical prophylaxis (resistance is increasing in *B. fragilis*)

-   Upper respiratory tract infections, CAP, gonorrhea,...but these are "in between" antibiotics and often passed over for better options

## 3rd generation cephalosporins {.smaller}

<br>

![](images/3rdgen.png){fig-align="center" width="400"}

## 3rd generation cephalosporins <br> spectrum of activity <br> <br>

![](images/3rdgenspectrum.png){fig-align="center"}

## Pharmacokinetics: 3rd generation cephalosporins {.smaller}

<br>

+-------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------+
| **Absorption**    | cefpodoxime (56%); cefexime (50%); cefoperazone (IV); ceftazidime (IV); cefotaxime (IV); ceftriaxone (IV, IM)                                                                               |        |
+-------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------+
| **Distribution**  | -   0.15-0.93 L/kg                                                                                                                                                                          |        |
|                   |                                                                                                                                                                                             |        |
|                   | -   Protein binding: \<10% ceftazidime; 30-70% cefotaxime, cefpodoxime, cefixime; \> 85-90% cefoperazone, ceftriaxone                                                                       |        |
|                   |                                                                                                                                                                                             |        |
|                   | -   CSF/Blood \> 10%: cefotaxime, ceftazidime; ceftriaxone,                                                                                                                                 |        |
+-------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------+
| **Metabolism**    | -   No metabolism                                                                                                                                                                           |        |
|                   |                                                                                                                                                                                             |        |
|                   | -   t½: cefotaxime, ceftazidime, cefoperazone; 1.5-2 hr; cefpodoxime 2.5 hr; cefixime 3hr; ceftriaxone 8 hr;                                                                                |        |
+-------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------+
| **Elimination**   | All renal except: ceftriaxone and cefoperazone undergo primarily biliary elimination                                                                                                        |        |
+-------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------+
| **PK:PD target**  | ≥ 40-50% *f*Time~\>MIC~                                                                                                                                                                     |        |
+-------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------+
| **Typical doses** | Cefotaxime 2 grams IV q8h; cefpodoxime 200-400 mg BID; ceftazidime 1-2 gram IV q8h or 15 mg/kg LD then 6 G IV over 24h; ceftriaxone 1-2 grams IV 24h (q12h meningitis); cefixime 400 mg BID |        |
|                   |                                                                                                                                                                                             |        |
|                   | Cephalexin 250-1000 mg QID                                                                                                                                                                  |        |
+-------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------+

::: aside
Source: Sanford Guide
:::

## 3rd generation cephalosporins: <br> Role in treatment

-   Extended gram-negative bacteria coverage, often used to treat gram-negative infections resistant to the first- and second-generation or other β-lactam antimicrobials
-   Ceftriaxone and cefotaxime penetrate the blood-brain barrier and cover bacteria in the cerebral spinal fluid,
    -   Ceftriaxone can be prescribed to treat meningitis caused by *H influenzae*, *Neisseria meningitidis*, or *Streptococcus pneumoniae.* 
    -   Ceftriaxone is also used to treat gonorrhea and disseminated Lyme disease.
    -   Ceftazidime has *Pseudomonas aeruginosa* coverage

## Key issues with ceftriaxone dosing {.small}

<br>

-   Often avoided in neonates, because of displacement of bilirubin (cefotaxime used instead)
-   2 gram q24h dose has largely replaced 1 gram dose for most indications (obesity, safety, improved PK/PD target attainment in critically ill)
    -   Risk for low exposure: low albumin, augmented renal clearance, sepsis
    -   Protein binding a key component that slows ceftriaxone clearance
-   Meningitis dose: 2 gram IV q12h

## Higher failure rates of 2nd and <br> 3rd generation cephalosporins for MSSA? {.small}

<br>

-   MSSA MIC breakpoints historically have been too high (MIC ≤ 8) vs. gram negatives (MIC ≤ 1, set to address ESBL test problems)
    -   Oxacillin and cefoxitin susceptibility are probably not a good predictor of ceftriaxone susceptibility among MSSA
-   In vitro, killing by ceftriaxone (esp. in presence of albumin) is much slower then anti-staphylococcal PCNs
-   In clinical PK/PD analysis, ceftriaxone 2 grams daily had a clinical failure rate of 55%, which was almost the same as vancomycin 1 gram Q12
    -   Ceftriaxone 2 gram q12 needed to give the best chance of covering MSSA
    -   OPAT convenience: cefazolin 2 gram q12h or daptomycin 6-8 mg/kg once daily
-   Conflicting observational clinical studies whether ceftriaxone is inferior

::: aside
[@paul.etal_2011; @zelenitsky.etal_2018]
:::

## Ceftriaxone for enterococcal endocarditis? {.smaller}

-   Aminoglycoside sparing regimens for *E. faecalis* endocarditis: Ceftriaxone + ampicillin
    -   *E. faecalis* has 5 PBPs
    -   At high doses, ampicillin will bind PBP 1,4,5 and ceftriaxone will bind PBPs 2,3
    -   Binding all 5 PBP creates remarkable synergy
    -   Need to use 2 gram IV q12h of ceftriaxone

![](images/Screenshot%202024-10-29%20at%2017.17.34.png){width="1000"}

::: aside
[@fernandez-hidalgo.etal_2013]
:::

## β-lactamases: Ambler classification {.smaller}

![](images/Ambler.png){fig-align="center" width="800"}

## ESBL resistance

<iframe width="1200" height="900" src="https://resistancemap.onehealthtrust.org/AntibioticResistance.php" title="Resistance Map">

</iframe>

## Ceftazidime-avibactam

![](images/carbapenemase_spectrum.png){fig-align="center"}

::: aside
[@tamma.hsu_2019] <br> Green, susceptibility anticipated to be \>80%; yellow, susceptibility antic- ipated to be 30% to 80%; red, intrinsic resistance or susceptibility anticipated to be \<30%.
:::

## 4th, 5th and 6th generation cephalosporins {fig-align="center"}

<br>

![](images/5th%20and6th.png){fig-align="center" width="600"}

## Spectrum of activity

<br>

![](images/specterum5thand6th.png){fig-align="center"}

## References

<br>

<br>